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Background: Prolonged QRS duration is associated with increased morbidity and mortality among patients with a reduced ejection fraction (EF)/
congestive heart failure (CHF). However, this association is poorly studied among patients with atrial fibrillation (AF). Our objective was to determine 
whether AF patients enrolled in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study with a prolonged QRS are at 
increased risk for death and hospitalization.
Methods: There were 3,959 patients in the AFFIRM trial with QRS duration measured at baseline, of whom 996 had heart failure (HF) defined as a 
history of CHF and/or reduced EF (≤ 45%). Cox models were applied to the data, relating the hazard ratio (HR) of all-cause/cardiovascular mortality 
and hospitalizations. QRS duration was expressed in milliseconds (ms) and divided into three categories ≥130 ms, 100-129 ms, or < 100 ms with 
the latter as the reference category, both among patients with and without heart failure, while controlling for multiple potential clinical confounders.
Results: Overall, 633/3,959 patients died during follow-up, including 290 patients with HF. A cardiovascular cause of mortality was identified in 
317 patients, of those 179 had HF. Among all patients with HF, a QRS duration between 100-129 elevated the HR of cardiovascular and all cause 
mortality by an estimated factor of 1.52 (95% CI 1.06 to 2.17, p = 0.022) and 1.52 (95% CI 1.15 to 2, p = 0.0029) respectively. Similarly, a QRS 
duration ≥130 increased cardiovascular and all cause mortality by a factor of 1.61 (95% CI 1.06 to 2.46, p = 0.027) and 1.51 (95% CI 1.08 to 2.1, 
p = 0.016). In contrast, there was no significant association of QRS duration with overall (p = 0.84) or cardiovascular mortality (p = 0.405) among 
patients without HF. Finally, QRS duration predicted cardiac hospitalization in all patients, with an increased HR of 1.16 (95% CI 1.03 to 1.32, p = 
0.014) for QRS 100-129 and of 1.38 (CI 95% 1.15 to 1.65, p = 0.001) for QRS ≥130.
Conclusion: In patients with AF and HF, a prolonged QRS duration increases the risk of cardiovascular and all cause mortality. A prolonged QRS 
was an independent predictor of increased cardiac hospitalizations in all patients with AF.
